Spending on oncology drugs increased to $25.9 billion in 2012 from $24.0 billion in 2011, a jump of 7.8%, even though overall spending on medicines in the United States declined by 3.5% during that time.

Although spending on medicines in the United States declined by 3.5% from 2011 to 2012, spending on oncology drugs continued to rise, with more money spent on these drugs than any other type. According to a report from the IMS Institute for Healthcare Informatics in Parsippany, NJ, spending on oncology drugs increased from $24 billion in 2011 to $25.9 billion in 2012. The increase was driven by spending on targeted therapies, as sales of hormonal agents and cytotoxic chemotherapies both declined slightly. Data reflect the invoice prices paid to wholesalers and pharmaceutical companies. [Source: IMS Institute for Healthcare Informatics]
View largeDownload slide

Although spending on medicines in the United States declined by 3.5% from 2011 to 2012, spending on oncology drugs continued to rise, with more money spent on these drugs than any other type. According to a report from the IMS Institute for Healthcare Informatics in Parsippany, NJ, spending on oncology drugs increased from $24 billion in 2011 to $25.9 billion in 2012. The increase was driven by spending on targeted therapies, as sales of hormonal agents and cytotoxic chemotherapies both declined slightly. Data reflect the invoice prices paid to wholesalers and pharmaceutical companies. [Source: IMS Institute for Healthcare Informatics]

Although spending on medicines in the United States declined by 3.5% from 2011 to 2012, spending on oncology drugs continued to rise, with more money spent on these drugs than any other type. According to a report from the IMS Institute for Healthcare Informatics in Parsippany, NJ, spending on oncology drugs increased from $24 billion in 2011 to $25.9 billion in 2012. The increase was driven by spending on targeted therapies, as sales of hormonal agents and cytotoxic chemotherapies both declined slightly. Data reflect the invoice prices paid to wholesalers and pharmaceutical companies. [Source: IMS Institute for Healthcare Informatics]
View largeDownload slide

Although spending on medicines in the United States declined by 3.5% from 2011 to 2012, spending on oncology drugs continued to rise, with more money spent on these drugs than any other type. According to a report from the IMS Institute for Healthcare Informatics in Parsippany, NJ, spending on oncology drugs increased from $24 billion in 2011 to $25.9 billion in 2012. The increase was driven by spending on targeted therapies, as sales of hormonal agents and cytotoxic chemotherapies both declined slightly. Data reflect the invoice prices paid to wholesalers and pharmaceutical companies. [Source: IMS Institute for Healthcare Informatics]

Close modal

For more news on cancer research, visit Cancer Discovery online at http://CDnews.aacrjournals.org.

©2013 American Association for Cancer Research.
2013